Skip to content

Universal Transvaginal Cervical Length Screening Program for Prevention of Preterm Birth in Singletons Without Prior Preterm Birth

Universal Transvaginal Cervical Length Screening Program for Prevention of Preterm Birth in Singletons Without Prior Preterm Birth: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03591042
Enrollment
1334
Registered
2018-07-18
Start date
2018-07-21
Completion date
2022-03-01
Last updated
2021-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Brief summary

This is a non-blinded randomized screening trial of asymptomatic singleton pregnancies without prior spontaneous preterm birth who are randomized to either transvaginal ultrasound cervical length screening program (i.e. intervention group) or no screening (i.e. control group). Women are consented and randomized at the time of their routine anatomy scan between 18 0/7 and 23 6/7 weeks. Women randomized in the transvaginal ultrasound cervical length screening will receive a single transvaginal ultrasound cervical length measurement after the anatomy scan. The cervical length will be measured by operators with certification of competence in the technique.

Interventions

DIAGNOSTIC_TESTcervical length screening

transvaginal ultrasound cervical length

Sponsors

Federico II University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

are: * Singleton gestations * No prior SPTB

Exclusion criteria

are: * Multiple gestations * History of SPTB in a prior pregnancy * Rupture of membranes at the time of randomization * Known major fetal structural (i.e. defined as those that are lethal or require prenatal or postnatal surgery) or chromosomal abnormality * Fetal death at the time of randomization * Cerclage in situ at the time of randomization * Pessary in situ at the time of randomization * Vaginal bleeding at the time of randomization * Women who are unconscious, severly ill, mentally handicapped, or under the age of 18 years.

Design outcomes

Primary

MeasureTime frameDescription
preterm birth rateLess than 37 weekseither spontaneous or indicated preterm delivery

Secondary

MeasureTime frameDescription
admission to neonatal intensive care unittime of delivery
neonatal deathBetween birth and 28 days of age
preterm birth rateess than 24, 28, 32, 30, and 34 weeks gestationeither spontaneous or indicated preterm delivery
Composite of adverse perinatal outcomesBetween birth and 28 days of ageNumber of neonates who will have at least one of the following: necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH) (grade 3 or higher), respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), retinopathy (ROP), blood-culture proven sepsis and neonatal death
perinatal deathBetween birth and 28 days of ageeither fetal or neonatal mortality
birth weighttime of deliveryweight of the baby at the time of delivery

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026